Cassava is a key crop in Vietnam. Therefore, reducing emissions in cassava cultivation will contribute significantly to ...

After hours: October 18 at 7:51 PM EDT Loading Chart for SAVA ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a ...

Cassava Sciences paid $40m after the SEC raised a case about alleged misleading data ... This is not the first controversy in the Alzheimer’s field, with Biogen and Eisai’s Aduhelm (aducanumab) having ...

Throughout the world, an estimated 800 million people consider cassava root a staple part of their diet. This starchy tuber—also known as yuca, Brazilian arrowroot, and manioc—first originated in ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial ...

An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under scrutiny.